Mevrometostat
Castration-Resistant Prostate Carcinoma
Prostate Cancer Clinical Trials ConsortiumSmall moleculePhase 3Active
BB
70/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 58/ 100
- Competitive Position
- 95/ 100
Competitive context
214 Active assets in the Castration-Resistant Prostate Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Darolutamide Bayer | Phase 4 | BBB |
Enzalutamide Prostate Cancer Clinical Trials Consortium | Phase 4 | BBB |
Prednisolone Ding-Wei Ye | Phase 4 | BBB |
Radium Ra-223 University of California, San Francisco | Phase 4 | BB |
Cabozantinib Rana McKay, MD | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Mevrometostat is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →